Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Skin Diseases and Disorders

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

Factors Affecting the Risk of Infection

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for SSc cohort.

Arthritis research & therapy·2026

Same author

Association of an app-based intervention with improvements in mobility, trunk muscle strength and patient-reported disease activity in axial spondyloarthritis: a 24-week pre-post study.

Therapeutic advances in musculoskeletal disease·2026

Same author

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026

Same author

Declining venom immunotherapy: patient characteristics and clinical outcomes.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2026

Same author

CXCR4-targeted PET/CT in early systemic sclerosis-associated interstitial lung disease: a prospective proof-of-concept study of in vivo inflammatory activity.

European journal of nuclear medicine and molecular imaging·2026

Same author

Patient-Centered Lupus Erythematosus Mobile Apps: Systematic Search and Cross-Sectional Evaluation by Patients and Physicians.

JMIR mHealth and uHealth·2026

Search research articles

Related Experiment Video

Updated: Dec 13, 2025

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Immunizations in immunocompromised patients: a guide for dermatologists.

Sophia Mohme¹, Marc Schmalzing², Cornelia S L Müller³

¹Department of Dermatology, Venereology and Allergology, University Hospital, Würzburg, Germany.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

|July 27, 2020

Summary

Immunomodulatory agents in dermatology necessitate specific vaccination guidelines. Patients on immunosuppression should receive standard, flu, pneumococcal, and zoster vaccines, with others based on risk, prioritizing safety and efficacy.

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

Related Experiment Videos

Last Updated: Dec 13, 2025

Murine Model of Epicutaneously-Induced Immunomodulation

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

Area of Science:

Immunology
Dermatology
Vaccinology

Background:

Immunomodulatory agents are increasingly used in dermatology.
This necessitates specific immunization recommendations for dermatological patients undergoing immunosuppressive therapy.
The German Standing Committee on Vaccination (STIKO) provides updated guidelines.

Purpose of the Study:

To present current immunization recommendations for immunocompromised individuals, particularly dermatological patients.
To guide healthcare professionals in counseling and initiating necessary vaccinations in this vulnerable group.

Main Methods:

Review of current recommendations from STIKO and relevant literature.
Focus on standard, seasonal, and additional vaccinations for dermatological patients.
Consideration of contraindications, intervals, and specific agents like rituximab.

Main Results:

Dermatological patients on immunosuppression should receive standard immunizations, plus flu, pneumococcal, and herpes zoster vaccines.
Additional vaccines (Haemophilus influenzae type B, hepatitis B, meningococci) may be indicated based on individual risk.
Live-attenuated vaccines have strict limitations; no vaccines (except flu) are recommended within six months post-rituximab therapy.

Conclusions:

Adherence to updated immunization guidelines is crucial for dermatological patients on immunosuppressive treatment.
Individualized vaccination strategies are necessary, considering specific immunosuppressive agents and patient comorbidities.
Competent counseling and timely vaccination are essential to protect immunocompromised dermatological patients from vaccine-preventable diseases.